BACKGROUND: Induction of a humoral response against amyloid-β peptide may be beneficial for Alzheimer's disease (AD) patients and may alleviate the onset and progression of AD. DNA-based vaccination provides a unique alternative method of immunization for treatment and prevention of AD. Currently, the two major delivery methods used for enhancing DNA uptake and immune responses to DNA vaccines in humans are electroporation (EP) and gene gun (GG). OBJECTIVE: The goal of this translational study was to evaluate the efficacy of an AD DNA epitope vaccine (DepVac) delivered intramuscularly by EP or intradermally by GG. METHODS: Humoral and cellular immune responses to immunization with DepVac were evaluated by ELISA and ELISPOT, respectively. Functional activity of the antibodies was also assessed. RESULTS: EP- and GG-mediated immunizations with DepVac induced similar anti-amyloid-β (Aβ) antibody and T cell responses. Anti-Aβ antibodies bound to amyloid plaques in AD brain tissue and to toxic forms of Aβ(42) peptide. CONCLUSION: Both delivery methods are effective at promoting potent antibodies specific for Aβ.
BACKGROUND: Induction of a humoral response against amyloid-β peptide may be beneficial for Alzheimer's disease (AD) patients and may alleviate the onset and progression of AD. DNA-based vaccination provides a unique alternative method of immunization for treatment and prevention of AD. Currently, the two major delivery methods used for enhancing DNA uptake and immune responses to DNA vaccines in humans are electroporation (EP) and gene gun (GG). OBJECTIVE: The goal of this translational study was to evaluate the efficacy of an AD DNA epitope vaccine (DepVac) delivered intramuscularly by EP or intradermally by GG. METHODS: Humoral and cellular immune responses to immunization with DepVac were evaluated by ELISA and ELISPOT, respectively. Functional activity of the antibodies was also assessed. RESULTS: EP- and GG-mediated immunizations with DepVac induced similar anti-amyloid-β (Aβ) antibody and T cell responses. Anti-Aβ antibodies bound to amyloid plaques in AD brain tissue and to toxic forms of Aβ(42) peptide. CONCLUSION: Both delivery methods are effective at promoting potent antibodies specific for Aβ.
Authors: A Luxembourg; D Hannaman; E Nolan; B Ellefsen; G Nakamura; L Chau; O Tellez; S Little; R Bernard Journal: Vaccine Date: 2008-04-16 Impact factor: 3.641
Authors: S Gilman; M Koller; R S Black; L Jenkins; S G Griffith; N C Fox; L Eisner; L Kirby; M Boada Rovira; F Forette; J-M Orgogozo Journal: Neurology Date: 2005-05-10 Impact factor: 9.910
Authors: Suzanne Jones; Kirsten Evans; Hilary McElwaine-Johnn; Michaela Sharpe; John Oxford; Rob Lambkin-Williams; Tim Mant; Andrew Nolan; Maria Zambon; Joanna Ellis; John Beadle; Peter T Loudon Journal: Vaccine Date: 2009-02-24 Impact factor: 3.641
Authors: Nina Movsesyan; Anahit Ghochikyan; Mikayel Mkrtichyan; Irina Petrushina; Hayk Davtyan; Purevdorj B Olkhanud; Elizabeth Head; Arya Biragyn; David H Cribbs; Michael G Agadjanyan Journal: PLoS One Date: 2008-05-07 Impact factor: 3.240
Authors: Hayk Davtyan; Anahit Ghochikyan; Armine Hovakimyan; Irina Petrushina; Jianmei Yu; David Flyer; Peter Juul Madsen; Lars Ostergaard Pedersen; David H Cribbs; Michael G Agadjanyan Journal: J Neuroimmunol Date: 2014-01-15 Impact factor: 3.478